VYNE Therapeutics Statistics
Total Valuation
VYNE has a market cap or net worth of $19.99 million. The enterprise value is -$9.02 million.
Important Dates
The next estimated earnings date is Thursday, March 5, 2026, before market open.
| Earnings Date | Mar 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
VYNE has 33.29 million shares outstanding. The number of shares has increased by 7.39% in one year.
| Current Share Class | 33.29M |
| Shares Outstanding | 33.29M |
| Shares Change (YoY) | +7.39% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 2.47% |
| Owned by Institutions (%) | 28.09% |
| Float | 32.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 35.06 |
| Forward PS | 24.49 |
| PB Ratio | 0.72 |
| P/TBV Ratio | 0.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.53
| Current Ratio | 12.53 |
| Quick Ratio | 12.11 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -66.96% and return on invested capital (ROIC) is -46.51%.
| Return on Equity (ROE) | -66.96% |
| Return on Assets (ROA) | -38.31% |
| Return on Invested Capital (ROIC) | -46.51% |
| Return on Capital Employed (ROCE) | -107.15% |
| Weighted Average Cost of Capital (WACC) | 15.41% |
| Revenue Per Employee | $43,846 |
| Profits Per Employee | -$2.04M |
| Employee Count | 13 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, VYNE has paid $4,000 in taxes.
| Income Tax | 4,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -76.45% in the last 52 weeks. The beta is 2.03, so VYNE's price volatility has been higher than the market average.
| Beta (5Y) | 2.03 |
| 52-Week Price Change | -76.45% |
| 50-Day Moving Average | 0.57 |
| 200-Day Moving Average | 0.63 |
| Relative Strength Index (RSI) | 62.47 |
| Average Volume (20 Days) | 396,857 |
Short Selling Information
The latest short interest is 549,047, so 1.65% of the outstanding shares have been sold short.
| Short Interest | 549,047 |
| Short Previous Month | 544,777 |
| Short % of Shares Out | 1.65% |
| Short % of Float | 1.69% |
| Short Ratio (days to cover) | 1.36 |
Income Statement
In the last 12 months, VYNE had revenue of $570,000 and -$26.48 million in losses. Loss per share was -$0.62.
| Revenue | 570,000 |
| Gross Profit | 570,000 |
| Operating Income | -29.75M |
| Pretax Income | -26.73M |
| Net Income | -26.48M |
| EBITDA | -29.73M |
| EBIT | -29.75M |
| Loss Per Share | -$0.62 |
Full Income StatementBalance Sheet
The company has $29.01 million in cash and n/a in debt, with a net cash position of $29.01 million or $0.87 per share.
| Cash & Cash Equivalents | 29.01M |
| Total Debt | n/a |
| Net Cash | 29.01M |
| Net Cash Per Share | $0.87 |
| Equity (Book Value) | 27.77M |
| Book Value Per Share | 0.83 |
| Working Capital | 27.62M |
Full Balance SheetCash Flow
| Operating Cash Flow | -33.12M |
| Capital Expenditures | n/a |
| Free Cash Flow | -38.48M |
| FCF Per Share | -$1.16 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -5,219.12% |
| Pretax Margin | -4,689.82% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
